Kun Yang, PhD
Senior Principal Scientist
Bristol Myers Squibb
Princeton, New Jersey
To provide a forum for academic, industry and regulatory colleagues to engage, align and communicate more effectively on immunogenicity topics related to drug development. The scope is modality agnostic and pertains to immunogenicity risk identification and mitigation through proactively understanding relevance and immunogenicity data interpretation in the context of non-clinical and clinical studies, data reporting and harmonization outputs and terminology.